| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Jenna Brashear
Cynthia McLaughlin
Rosalio Madrigal
Rosalio Madrigal
| Share Statistics | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $712.7 | $288.9 | 41% |
|
| Shares Out (Mil) | 0.1 | 54.0 | 1% |
|
| Institutional Ownership | 100.0% | 93.1% | 99% |
|
| Float (Mil) | 35.8 | 41.4 | 40% |
|
| Beta | 0.36 | 0.94 | 21% |
|
| Avg Daily Volume (000s) | 260 | 480 | 49% |
|
| Price Change (52-week) |
(7.2%) | 59.9% | 40% |
|
| Growth | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 9 | |
| Current EPS | ($0.660) | ($2.682) | ($2.412) | |
| Month Ago EPS | ($0.561) | ($2.213) | ($2.106) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.559) | ($2.223) | ($2.141) | |
| Year/Year Chg | (99.9%) | (37.7%) | (43.3%) | |
| Financials | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($182) | ($43) | 7% |
|
| EPS (TTM) | ($5.844) | ($1.500) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($151) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $23 | $2 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $386 | $190 | 31% |
|
| Valuation | BBOT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.21 | 2.84 | 54% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (69.0%) | (47.7%) | 9% |
|
| ROE | (381.9%) | (55.0%) | 2% |
|
| Liabilities to Assets | 14.2% | 29.6% | 9% |
|
| F-Score | 1 | 3 | na |
|
Passing Stock Screens
As of 9/2/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 3.3% |
| +/- S&P 500: | -4.2 |
| Performance Since Inception: | 2.8% |
| +/- S&P 500: | -4.7 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
